Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

InflaRx N.V.. (1/4/18). "Press Release: InflaRx to Present at Upcoming Investor Conferences". Jena.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation InflaRx N.V. (Nasdaq Global Select Market: IFRX)
  Group InflaRx (Group)
  Organisation 2 Leerink Partners LLC
  Today SVB Leerink LLC
Products Product J.P. Morgan 36th Annual Healthcare Conference 2018 San Francisco
  Product 2 Leerink Partners Annual Global Healthcare Conference 2018 New York
Index terms Index term InflaRx–JPMorgan Chase: investor conference, 201801 supply service InflaRx presents at JP Morgan Healthcare Conference 2018
  Index term 2 InflaRx–Leerink: investor conference, 201802 supply service InflaRx presents at Leerink Partners Global Healthcare Conference 2018
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Christ, Arnd (InflaRx 201506– CFO before Proteros + MediGene + NovImmune + Probiodrug + Hoechst)

InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, will present at the following conferences:

J.P. Morgan Annual Healthcare Conference

Date: January 8-11, 2018,
Presentation: Wed, 10th Jan 8:00 am PST (5:00 pm CET)
Venue: San Francisco, CA, USA
Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx
Arnd Christ, Chief Financial Officer of InflaRx

LEERINK Partners 7th Annual Global Healthcare Conference

Date: February 14-15, 2018
Presentation: Wed, 14th Feb 1:30 pm EST (7:30 pm CET)
Venue: New York, NY, USA
Presenter: Prof. Niels Riedemann, Chief Executive Officer of InflaRx

Live webcasts of the presentations will be provided at through the “Events & Presentations” section on the “Investors” page. A replay of the presentations will be available from InflaRx’s website following the conferences.

About InflaRx N.V.:

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the NASDAQ Global Select Market in the United States under the trading symbol “IFRX.”


InflaRx N.V.

Prof. Dr. Niels C. Riedemann - CEO
Email: info[at]
Tel: +49-3641-508180

MC Services AG

Katja Arnold, Andreas Jungfer
Email: inflarx[at]
Tel: +49-89-210 2280

Record changed: 2018-01-09


Picture [LSA] – The Business Web Portal 650x89px

More documents for InflaRx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top